A nurse is reviewing the chart of a client who is scheduled to have radiological studies of the kidneys performed with the use of IV contrast dye. Which of the following client medications should the nurse withhold prior to the examination?

A. Simvastatin: This HMG-CoA reductase inhibitor is used for lipid management and does not interact with iodinated contrast media to cause renal injury. There is no pharmacological contraindication for continuing statin therapy before a radiological study. Withholding this medication is unnecessary and does not provide protective benefits for the kidneys. B. Pantoprazole: As a proton pump inhibitor, this medication manages gastric acid secretion and has no known synergistic toxicity with IV contrast dyes. It does not influence the hemodynamic or excretory functions of the renal system. Continuation of pantoprazole does not increase the risk of contrast-induced nephropathy or metabolic complications. C. Valsartan: This angiotensin II receptor blocker is used for blood pressure control and is not typically withheld specifically for contrast studies unless acute kidney injury is already present. While it affects renal perfusion, it does not carry the same metabolic risk as other diabetic medications. Standard protocol allows for the administration of this drug pre-procedure. D. Metformin: This medication must be withheld prior to and for 48 hours after contrast administration due to the risk of lactic acidosis. Contrast dye can cause transient renal impairment, leading to the accumulation of metformin in the bloodstream. Excessive metformin levels trigger a dangerous shift in systemic pH, resulting in metabolic acidosis.